A study published in the journal CANCER examined the effect of the time of day of administration of immunochemotherapy in 397 patients with advanced small cell lung cancer in China from May 2019 to October 2023.[1] Patients received the drugs atezolizumab or durvalumab along with chemotherapy.[1] A randomized phase III clinical trial showed that patients treated before 3:00 PM had significantly longer progression-free survival and overall survival compared to those treated later.[1][2][5] After adjusting for confounding factors, earlier administration time was associated with a 52% lower risk of cancer progression and a 63% lower risk of death.[1] Patients treated before 3:00 PM lived almost twice as long as those treated later in the afternoon.[2] Adjusting the infusion time is a simple intervention at no additional cost with immediate clinical utility.[1]